AVR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Anteris Technologies (AVR) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has promising technology in a growing market and positive analyst ratings, the lack of immediate trading signals, weak financial performance, and recent price decline suggest waiting for further clarity or a better entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 49.32, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 5.132, with resistance at 5.804.
Anteris is developing a differentiated TAVR platform, DurAVR, targeting a $12.4 billion market. The company has received strategic investment from Medtronic, validating its technology. Analysts have issued Overweight ratings with price targets significantly higher than the current price.
The stock has shown a recent price decline, with a post-market drop of -6.17%. Financial performance is weak, with declining revenue (-42.18% YoY) and negative net income, although losses have narrowed. There are no significant hedge fund or insider trading trends, and no recent Congress trading data.
In Q4 2025, revenue dropped by 42.18% YoY to $310,000. Net income improved but remains negative at -$29.2 million. EPS increased to -0.74, and gross margin improved to 70.65%. While there are signs of operational improvement, the financials remain weak overall.
Analysts are optimistic, with Overweight ratings and price targets ranging from $15 to $17, citing the potential of DurAVR to disrupt the TAVR market. However, recent price target reductions reflect the impact of financing and market conditions.
